Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer

Pyong Gon Moon, Jeong Eun Lee, Young Eun Cho, Soo Jung Lee, Yee Soo Chae, Jin Hyang Jung, In-San Kim, Ho Yong Park, Moon Chang Baek

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Extracellular vesicles (EVs) secreted from cancer cells have potential for generating cancer biomarker signatures. Fibronectin (FN) was selected as a biomarker candidate, due to the presence in surface on EVs secreted from human breast cancer cell lines. A subsequent study used two types of enzyme-linked immunosorbent assays (ELISA) to determine the presence of these proteins in plasma samples from diseasefree individuals (n=70), patients with BC (n=240), BC patients after surgical resection (n=40), patients with benign breast tumor (n=55), and patients with non-cancerous diseases (thyroiditis, gastritis, hepatitis B, and rheumatoid arthritis; n=80). FN levels were significantly elevated (p < .0001) at all stages of BC, and returned to normal after tumor removal. The diagnostic accuracy for FN detection in extracellular vesicles (ELISA method 1) (area under the curve, 0.81; 95% CI, 0.76 to 0.86; sensitivity of 65.1% and specificity of 83.2%) were also better than those for FN detection in the plasma (ELISA method 2) (area under the curve, 0.77; 95% CI, 0.72 to 0.83; sensitivity of 69.2% and specificity of 73.3%) in BC. The diagnostic accuracy of plasma FN was similar in both the early-stage BC and all BC patients, as well as in the two sets. This liquid biopsy to detect FN on circulating EVs could be a promising method to detect early breast cancer.

Original languageEnglish
Pages (from-to)40189-40199
Number of pages11
JournalOncotarget
Volume7
Issue number26
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Fibronectins
Breast Neoplasms
Biopsy
Enzyme-Linked Immunosorbent Assay
Area Under Curve
Sensitivity and Specificity
Thyroiditis
Gastritis
Tumor Biomarkers
Hepatitis B
Extracellular Vesicles
Blood Proteins
Rheumatoid Arthritis
Neoplasms
Biomarkers
Cell Line

Keywords

  • Breast cancer
  • Diagnosis
  • ELISA
  • Extracellular vesicle

ASJC Scopus subject areas

  • Oncology

Cite this

Moon, P. G., Lee, J. E., Cho, Y. E., Lee, S. J., Chae, Y. S., Jung, J. H., ... Baek, M. C. (2016). Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. Oncotarget, 7(26), 40189-40199. https://doi.org/10.18632/oncotarget.9561

Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. / Moon, Pyong Gon; Lee, Jeong Eun; Cho, Young Eun; Lee, Soo Jung; Chae, Yee Soo; Jung, Jin Hyang; Kim, In-San; Park, Ho Yong; Baek, Moon Chang.

In: Oncotarget, Vol. 7, No. 26, 01.01.2016, p. 40189-40199.

Research output: Contribution to journalArticle

Moon, PG, Lee, JE, Cho, YE, Lee, SJ, Chae, YS, Jung, JH, Kim, I-S, Park, HY & Baek, MC 2016, 'Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer', Oncotarget, vol. 7, no. 26, pp. 40189-40199. https://doi.org/10.18632/oncotarget.9561
Moon, Pyong Gon ; Lee, Jeong Eun ; Cho, Young Eun ; Lee, Soo Jung ; Chae, Yee Soo ; Jung, Jin Hyang ; Kim, In-San ; Park, Ho Yong ; Baek, Moon Chang. / Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 40189-40199.
@article{48ac20425b5c42a9999cd6fd83e3f9d6,
title = "Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer",
abstract = "Extracellular vesicles (EVs) secreted from cancer cells have potential for generating cancer biomarker signatures. Fibronectin (FN) was selected as a biomarker candidate, due to the presence in surface on EVs secreted from human breast cancer cell lines. A subsequent study used two types of enzyme-linked immunosorbent assays (ELISA) to determine the presence of these proteins in plasma samples from diseasefree individuals (n=70), patients with BC (n=240), BC patients after surgical resection (n=40), patients with benign breast tumor (n=55), and patients with non-cancerous diseases (thyroiditis, gastritis, hepatitis B, and rheumatoid arthritis; n=80). FN levels were significantly elevated (p < .0001) at all stages of BC, and returned to normal after tumor removal. The diagnostic accuracy for FN detection in extracellular vesicles (ELISA method 1) (area under the curve, 0.81; 95{\%} CI, 0.76 to 0.86; sensitivity of 65.1{\%} and specificity of 83.2{\%}) were also better than those for FN detection in the plasma (ELISA method 2) (area under the curve, 0.77; 95{\%} CI, 0.72 to 0.83; sensitivity of 69.2{\%} and specificity of 73.3{\%}) in BC. The diagnostic accuracy of plasma FN was similar in both the early-stage BC and all BC patients, as well as in the two sets. This liquid biopsy to detect FN on circulating EVs could be a promising method to detect early breast cancer.",
keywords = "Breast cancer, Diagnosis, ELISA, Extracellular vesicle",
author = "Moon, {Pyong Gon} and Lee, {Jeong Eun} and Cho, {Young Eun} and Lee, {Soo Jung} and Chae, {Yee Soo} and Jung, {Jin Hyang} and In-San Kim and Park, {Ho Yong} and Baek, {Moon Chang}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9561",
language = "English",
volume = "7",
pages = "40189--40199",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer

AU - Moon, Pyong Gon

AU - Lee, Jeong Eun

AU - Cho, Young Eun

AU - Lee, Soo Jung

AU - Chae, Yee Soo

AU - Jung, Jin Hyang

AU - Kim, In-San

AU - Park, Ho Yong

AU - Baek, Moon Chang

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Extracellular vesicles (EVs) secreted from cancer cells have potential for generating cancer biomarker signatures. Fibronectin (FN) was selected as a biomarker candidate, due to the presence in surface on EVs secreted from human breast cancer cell lines. A subsequent study used two types of enzyme-linked immunosorbent assays (ELISA) to determine the presence of these proteins in plasma samples from diseasefree individuals (n=70), patients with BC (n=240), BC patients after surgical resection (n=40), patients with benign breast tumor (n=55), and patients with non-cancerous diseases (thyroiditis, gastritis, hepatitis B, and rheumatoid arthritis; n=80). FN levels were significantly elevated (p < .0001) at all stages of BC, and returned to normal after tumor removal. The diagnostic accuracy for FN detection in extracellular vesicles (ELISA method 1) (area under the curve, 0.81; 95% CI, 0.76 to 0.86; sensitivity of 65.1% and specificity of 83.2%) were also better than those for FN detection in the plasma (ELISA method 2) (area under the curve, 0.77; 95% CI, 0.72 to 0.83; sensitivity of 69.2% and specificity of 73.3%) in BC. The diagnostic accuracy of plasma FN was similar in both the early-stage BC and all BC patients, as well as in the two sets. This liquid biopsy to detect FN on circulating EVs could be a promising method to detect early breast cancer.

AB - Extracellular vesicles (EVs) secreted from cancer cells have potential for generating cancer biomarker signatures. Fibronectin (FN) was selected as a biomarker candidate, due to the presence in surface on EVs secreted from human breast cancer cell lines. A subsequent study used two types of enzyme-linked immunosorbent assays (ELISA) to determine the presence of these proteins in plasma samples from diseasefree individuals (n=70), patients with BC (n=240), BC patients after surgical resection (n=40), patients with benign breast tumor (n=55), and patients with non-cancerous diseases (thyroiditis, gastritis, hepatitis B, and rheumatoid arthritis; n=80). FN levels were significantly elevated (p < .0001) at all stages of BC, and returned to normal after tumor removal. The diagnostic accuracy for FN detection in extracellular vesicles (ELISA method 1) (area under the curve, 0.81; 95% CI, 0.76 to 0.86; sensitivity of 65.1% and specificity of 83.2%) were also better than those for FN detection in the plasma (ELISA method 2) (area under the curve, 0.77; 95% CI, 0.72 to 0.83; sensitivity of 69.2% and specificity of 73.3%) in BC. The diagnostic accuracy of plasma FN was similar in both the early-stage BC and all BC patients, as well as in the two sets. This liquid biopsy to detect FN on circulating EVs could be a promising method to detect early breast cancer.

KW - Breast cancer

KW - Diagnosis

KW - ELISA

KW - Extracellular vesicle

UR - http://www.scopus.com/inward/record.url?scp=84982995063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982995063&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9561

DO - 10.18632/oncotarget.9561

M3 - Article

C2 - 27250024

AN - SCOPUS:84982995063

VL - 7

SP - 40189

EP - 40199

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -